EuroPCR 2022 | The IMPROVED-CTO Trial

PCI success rate in chronic total occlusion (CTO), according to some registries, is below 80%. These failed revascularization procedures might lead to quality-of-life deterioration and shorter survival. This concern has driven the development of new techniques and technologies in an attempt to increase PCI success. Today, approximately 20% of CTOs are treated with a second procedure.

EuroPCR 2022 | The IMPROVED-CTO Trial

In this study, CTO plaque was modified with a technique also called Investment Technique, which consists of intentional dilation from proximal to distal cap with balloon, in patients with failed CTO PCI, aiming at improved success rate at repeat attempts. 

The aim was to determine whether drug coated balloons (DCB) could simplify a future procedure, reduce adverse events and improve procedural success vs. conventional balloons. 

This randomized multicenter study on 371 CTO patients, 44 with failed initial PCI (they randomized 22 patients to DCB and 22 to conventional balloon angioplasty). Primary end point was procedural success of second procedure, done 3 months after the first. Secondary end points were procedure duration, complexity, adverse events after one year and changes in quality of life. 

Read also: EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation.

The use of DCB resulted in increased procedural success the second time around, though non-significant (90% vs 81.8%), reduced procedural duration (33 vs 60min), lower amount of contrast (170 vs 334ml), reduced radiation exposure (1.7 vs 3.2 Gy). The composite of MACE at one year in addition to contrast induced nephropathy was better with DCB.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Amat-Santos, I. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...